Collaboration Between Shimadzu Corporation and the MacCoss Lab of Biological Mass Spectrometry, University of Washington - WBOY.com: Clarksburg, Morgantown: News, Sports, Weather

Collaboration Between Shimadzu Corporation and the MacCoss Lab of Biological Mass Spectrometry, University of Washington

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

Shimadzu seeks to redefine quantitative proteomics by enabling powerful Skyline software support on its ultra-fast mass spectrometry platforms.

Columbia, MD (PRWEB) July 14, 2014

Shimadzu Corporation announced today the release of the new mutual support between the Skyline quantitative proteomics software and Shimadzu's high-sensitivity triple quadrupole LC/MS/MS platform.

As mass spectrometry-based proteomics technologies continue to play an ever-increasing role in biomarker discovery, validation and translation for biological and clinical applications, advances in throughput and multiplexing are necessary to improve quantitation of biomarkers in this emerging field referred to as quantitative Clinical Chemistry Proteomics (qCCP). To bring qCCP applications closer to clinical laboratories, Shimadzu has integrated its ultra-fast LC/MS/MS platforms with the powerful, freely available Skyline quantitative proteomics software.

Skyline software can be used to design, refine and optimize Selected Reaction Monitoring (SRM) / Multiple Reaction Monitoring (MRM) and Full Scan MS and MS/MS quantitative methods based on protein sequences and user-defined rules. Skyline software not only integrates results with method optimization; it is also described as a common framework for quantitative proteomics for researchers to adopt and to standardize to.

Shimadzu has been an excellent collaborator to work with. Their effort to complete the integration with Skyline in such a rapid time scale has been impressive, said Brendan MacLean, Software Project Manager for Skyline at the University of Washington, School of Medicine, Department of Genome Sciences.

Dr. Michael MacCoss, Professor at the University of Washington, School of Medicine, Department of Genome Sciences, said, Skyline is a community effort in the field of quantitative proteomics. It is important to foster a broad sharing of both methods and results across instrument platforms. By including Shimadzus high-sensitivity triple quadrupole platforms into Skyline, it enables the proteomics community to work with far-reaching technologies."

We are now excited to redefine the quantitative proteomics market in collaboration with the MacCoss Lab and their outstanding software. MacCoss Lab has brought together Shimadzus class-leading mass spectrometry platforms and Skyline software to help enhance quantitative proteomics workflows. We will continue our effort to develop and provide the best solutions to our customers, said Kozo Miseki, Corporate Officer, Deputy General Manager of Analytical & Measuring Instruments Division, Shimadzu Corporation.

About Shimadzu Corporation
Founded in 1875, Shimadzu Corporation, a leader in the development of advanced technologies, has a distinguished history of innovation built on the foundation of contributing to society through science and technology. Shimadzu maintains a global network of sales, service, technical support and applications centers on six continents, and has established long-term relationships with a host of highly trained distributors located in over 100 countries. For more information, visit http://www.shimadzu.com.

About Skyline
Skyline is an open source software project, started in 2008 by the MacCoss lab at the University of Washington. It is now the leading software application for building Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM), Parallel Reaction Monitoring (PRM - Targeted MS/MS and DIA/SWATH) and targeted DDA with MS1 quantitative methods and analyzing the resulting mass spectrometer data. For more information, visit skyline.maccosslab.org.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12015348.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.